ADAMTS4 is a serum biomarker for pulmonary arterial hypertension associated with congenital heart disease
Authors:
Open Access
- 22 July 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1863052
Abstract
Objectives: Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a cardiopulmonary disorder characterized by pathological pulmonary vascular remodeling and perivascular inflammatory cell infiltration. ADAMTS4 is a secreted, zinc-dependent metalloprotease critically involved in extracellular matrix degradation and turnover and has recently emerged as a potential biomarker in vascular remodeling diseases. This study aimed to evaluate the diagnostic performance and prognostic value of serum ADAMTS4 in patients with PAH-CHD. Methods: This study included patients with PAH-CHD, patients with CHD, and healthy controls. Serum ADAMTS4 levels were measured by ELISA. Correlations with clinical parameters were assessed using Spearman’s rank correlation. The diagnostic efficacy was evaluated by ROC curve analysis. Univariate and multivariable logistic regression were used to identify independent risk factors associated with the presence of PAH-CHD. PAH-CHD patients were followed up for a median duration of 40.5 months, and Kaplan–Meier and Cox regression analyses were used to analyze prognosis. Results: Compared with those in CHD patients and healthy controls, serum ADAMTS4 levels were elevated in PAH-CHD patients. ADAMTS4 was positively correlated with NT-proBNP ( r = 0.45, p = 0.002), CRP ( r = 0.60, p < 0.001), and WHO functional class ( r = 0.49, p < 0.001). ROC analysis demonstrated good discriminatory ability for differentiating PAH-CHD from CHD (AUC = 0.78; 95% CI: 0.69–0.87; p < 0.001), with an optimal cutoff value of 42.2 ng/mL. After multivariable adjustment, logistic regression revealed that ADAMTS4 remained an independent factor associated with the presence of PAH-CHD (OR = 1.189; 95% CI: 1.036–1.365; p = 0.014). Kaplan–Meier analysis revealed significantly shorter event-free survival in patients with ≥ 42.2 ng/mL ADAMTS4 than in those with lower levels (log-rank p = 0.046). After multivariable adjustment, Cox regression confirmed ADAMTS4 as an independent predictor of adverse clinical events (HR = 1.038; 95% CI: 1.007–1.071; p = 0.017). Conclusion: Serum ADAMTS4 is elevated in patients with PAH-CHD and is correlated with disease severity and adverse outcomes. These findings support its utility as a noninvasive serum biomarker for diagnosis, risk stratification and prognostic assessment in PAH-CHD patients.Keywords
This publication has 29 references indexed in Scilit:
- Inflammatory and cardiac biomarkers in pulmonary arterial hypertension: The prognostic role of IL-34Heart & Lung, 2024
- Requirement for C-mannosylation to be secreted and activated a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4)Biochimica et Biophysica Acta (BBA) - General Subjects, 2021
- Molecular pathogenesis and current pathology of pulmonary hypertensionHeart Failure Reviews, 2015
- Platelet Distribution Width and Mean Platelet Volume in Idiopathic Pulmonary Arterial HypertensionHeart, Lung and Circulation, 2015
- Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classificationInternational Journal of Cardiology, 2014
- Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndromeClinical Research in Cardiology, 2010
- ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromesBiomedicine & Pharmacotherapy, 2010
- ADAMTS-4 and -8 are inflammatory regulated enzymes expressed in macrophage-rich areas of human atherosclerotic plaquesAtherosclerosis, 2008
- Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registryInternational Journal of Cardiology, 2007
- Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced CentersJACC, 2006